Eigen

Eigen is a health care startup based in the United States that specializes in an AI-ready radiology platform for analyzing multi-modality images, mpMRI, PET, and CT, as well as semi-robotic targeting hardware. The company has been operating since 1975 and is dedicated to bridging the gaps between radiology, urology, and oncology to improve healthcare and the quality of life. Eigen's innovative breakthroughs in image-guided disease diagnosis and treatment, particularly related to prostate cancer, have positioned them at the forefront of emerging technology in the medical field. Eigen holds numerous patents in its growing intellectual property portfolio and adheres to the highest standards of medical device regulatory compliance. With ISO 13485 certification, the company is aligned with international regulatory requirements and has the ability to pursue sales and distribution in various countries including Canada, the EU, Latin America, Iran, Turkey, China, Hong Kong, the Philippines, Korea, Turkey, India, Mexico, and the USA. As of now, there is no publicly available information about the last investment or the investors involved in Eigen. However, with its long-standing presence and expertise in the health care industry, Eigen presents an exciting opportunity for potential investors looking to be part of cutting-edge advancements in medical technology.